Adaptive Biotechnologies (NASDAQ:ADPT) Trading 7.3% Higher – Should You Buy?

Adaptive Biotechnologies Co. (NASDAQ:ADPT)’s stock price was up 7.3% during mid-day trading on Thursday . The company traded as high as $6.45 and last traded at $6.44. Approximately 102,666 shares were traded during trading, a decline of 93% from the average daily volume of 1,394,303 shares. The stock had previously closed at $6.00.

Analyst Ratings Changes

Several research analysts have recently commented on ADPT shares. Piper Sandler raised their target price on shares of Adaptive Biotechnologies from $6.00 to $7.00 and gave the stock an “overweight” rating in a report on Monday, November 11th. BTIG Research lifted their price objective on Adaptive Biotechnologies from $8.00 to $9.00 and gave the company a “buy” rating in a report on Wednesday, December 18th.

Adaptive Biotechnologies Trading Up 16.3 %

The company’s 50-day moving average is $5.82 and its 200-day moving average is $4.87. The firm has a market cap of $1.06 billion, a price-to-earnings ratio of -5.37 and a beta of 1.49.

Institutional Trading of Adaptive Biotechnologies

Large investors have recently bought and sold shares of the business. JTC Employer Solutions Trustee Ltd acquired a new stake in shares of Adaptive Biotechnologies during the 3rd quarter valued at $26,000. Ashton Thomas Securities LLC bought a new position in Adaptive Biotechnologies in the 3rd quarter valued at approximately $34,000. GAMMA Investing LLC acquired a new stake in Adaptive Biotechnologies during the 4th quarter worth approximately $59,000. MQS Management LLC bought a new stake in Adaptive Biotechnologies during the 2nd quarter worth approximately $36,000. Finally, Rothschild Investment LLC acquired a new position in Adaptive Biotechnologies in the 2nd quarter valued at approximately $36,000. 99.17% of the stock is owned by institutional investors and hedge funds.

Adaptive Biotechnologies Company Profile

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system.